antisense LNA (EZN-3042)
/ Enzon
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 28, 2020
Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma.
(PubMed, BMC Vet Res)
- "In conclusion, reduced survivin expression was demonstrated in lymphoma tissues in the majority of dogs treated with EZN-3042 at 8.25 mg/kg twice weekly, which was associated with minimal adverse effects. This dose may be used in future studies of EZN-3042/chemotherapy combinations in dogs with spontaneous lymphoma and other cancers."
Journal • P1 data • BIRC5
1 to 1
Of
1
Go to page
1